Why not treat human cancer with interleukin-1 blockade?

Cancer and Metastasis Reviews

Volumn 29, Issue 2, 2010, Pages 317-329

  Dinarello, Charles A ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Cytokines; Endothelium; Inflammasome; Inflammation; Innate immune response; Necrosis

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB;

ADD ON THERAPY; ANTIANGIOGENIC ACTIVITY; BLEEDING; BREAST CANCER; CARCINOGENESIS; CELL ADHESION; CHRONIC INFLAMMATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EDEMA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNE RESPONSE; LUNG CANCER; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SKIN DEFECT; THROMBOSIS; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77954551165     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-010-9229-0     Document Type: Review

References (125)

1. Balkwill, F., Charles, K. A., & Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7, 211-217.
2. Mantovani, A. (2005). Cancer: inflammation by remote control. Nature, 435, 752-753.
3. Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., et al. (2007). Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Research, 67, 1062-1071.
4. El-Omar, E. M., Carrington, M., Chow, W. H., McColl, K. E., Bream, J. H., Young, H. A., et al. (2001). The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature, 412, 99.
5. Glas, J., Torok, H. P., Schneider, A., Brunnler, G., Kopp, R., Albert, E. D., et al. (2004). Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric cancer. Journal of Clinical Oncology, 22, 4746-4752.
6. Hamajiama, N., Matsuo, K., Saito, T., Tajima, K., Okujma, K., Yamao, K., et al. (2001). Interleukin-1 polymorphims, lifestyle factors and Helicobacter pylori infection. Japanese Journal of Cancer Research, 92, 383-389.
7. Riedel, S., Kraft, M., Kucharzik, T., Pauels, H. G., Tiemann, M., Steinbuchel, A., et al. (2001). CD4+ Th1-cells predominate in low-grade B-cell lymphoma of gastric mucosa-associated lymphoid tissue (MALT type). Scandinavian Journal of Gastroenterology, 36, 1198-1203.
8. Gatti, L. L., Burbano, R. R., de Assumpcao, P. P., Smith, M. A., & Payao, S. L. (2004). Interleukin-1beta polymorphisms. Helicobacter pylori infection in individuals from Northern Brazil with gastric adenocarcinoma. Clinical and Experimental Medicine, 4, 93-98.
9. Chang, Y. W., Jang, J. Y., Kim, N. H., Lee, J. W., Lee, H. J., Jung, W. W., et al. (2005). Interleukin-1B (IL-1B) polymorphisms and gastric mucosal levels of IL-1beta cytokine in Korean patients with gastric cancer. International Journal of Cancer, 114, 465-471.
10. Germano, G., Allavena, P., & Mantovani, A. (2008). Cytokines as a key component of cancer-related inflammation. Cytokine, 43, 374-379.
11. Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., et al. (2009). Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clinic Proceedings, 84, 114-122.
12. Vidal-Vanaclocha, F., Alvarez, A., Asumendi, A., Urcelay, B., Tonino, P., & Dinarello, C. A. (1996). Interleukin 1 (IL-1) - dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. Journal of the National Cancer Institute, 88, 198-205.
13. Lewis, A. M., Varghese, S., Xu, H., & Alexander, H. R. (2006). Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. Journal of Translational Medicine, 4, 48.
14. Giavazzi, R., Garofalo, A., Bani, M. R., Abbate, M., Ghezzi, P., Boraschi, D., et al. (1990). Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Research, 50, 4771-4775.
15. Lauri, D., Bertomeu, M. C., Orr, F. W., Bastida, E., Sauder, D., & Buchanan, M. R. (1990). Interleukin-1 increases tumor cell adhesion to endothelial cells through an RGD dependent mechanism: in vitro and in vivo studies. Clinical & Experimental Metastasis, 8, 27-32.
16. Arguello, F., Baggs, R. B., Graves, B. T., Harwell, S. E., Cohen, H. J., & Frantz, C. N. (1992). Effect of IL-1 on experimental bone/bone-marrow metastases. International Journal of Cancer, 52, 802-807.
17. Mannel, D. N., Orosz, P., Hafner, M., & Falk, W. (1994). Mechanisms involved in metastasis enhanced by inflammatory mediators. Circulatory Shock, 44, 9-13.
18. Scherbarth, S., & Orr, F. W. (1997). Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: effects of interleukin-1alpha on metastasis and the location of B16F1 melanoma cell arrest. Cancer Research, 57, 4105-4110.
19. Chirivi, R. G., Chiodoni, C., Musiani, P., Garofalo, A., Bernasconi, S., Colombo, M. P., et al. (1996). IL-1alpha genetransfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. International Journal of Cancer, 67, 856-863.
20. Khatib, A. M., Kontogiannea, M., Fallavollita, L., Jamison, B., Meterissian, S., & Brodt, P. (1999). Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Research, 59, 1356-1361.
21. Vidal-Vanaclocha, F., Amezaga, C., Asumendi, A., Kaplanski, G., & Dinarello, C. A. (1994). Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Research, 54, 2667-2672.
22. Martin-Padura, I., Mortarini, R., Lauri, D., Bernasconi, S., Sanchez-Madrid, F., Parmiani, G., et al. (1991). Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. Cancer Research, 51, 2239-2241.
23. Garofalo, A., Chirivi, R. G., Foglieni, C., Pigott, R., Mortarini, R., Martin-Padura, I., et al. (1995). Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Research, 55, 414-419.
24. Dinarello, C. A. (2009). Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol, 27, 519-550.
25. Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D. A., et al. (2009). Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. The Journal of Biological Chemistry, 285, 6477-6488.
26. Song, X., Voronov, E., Dvorkin, T., Fima, E., Cagnano, E., Benharroch, D., et al. (2003). Differential effects of IL-1alpha and IL-1beta on tumorigenicity patterns and invasiveness. Journal of Immunology, 171, 6448-6456.
27. Chirivi, R. G., Garofalo, A., Padura, I. M., Mantovani, A., & Giavazzi, R. (1993). Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Research, 53, 5051-5054.
28. Weinreich, D. M., Elaraj, D. M., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., et al. (2003). Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Research, 63, 5957-5961.
29. Elaraj, D. M., Weinreich, D. M., Varghese, S., Puhlmann, M., Hewitt, S. M., Carroll, N. M., et al. (2006). The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clinical Cancer Research, 12, 1088-1096.
30. Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 100, 2645-2650.
31. Carmi, Y., Voronov, E., Dotan, S., Lahat, N., Rahat, M. A., Fogel, M., et al. (2009). The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. Journal of Immunology, 183, 4705-4714.
32. Coxon, A., Bolon, B., Estrada, J., Kaufman, S., Scully, S., Rattan, A., et al. (2002). Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis and Rheumatism, 46, 2604-2612.
33. Cunnane, G., Madigan, A., Murphy, E., FitzGerald, O., & Bresnihan, B. (2001). The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford), 40, 62-69.
34. Towbin, H., Schmitz, A., van Oostrum, J., Seitz, M., Dewald, B., Zingel, O., et al. (1994). Monoclonal antibody based enzymelinked and chemiluminescent assays for the human interleukin-1 receptor antagonist. Application to measure hIL-1ra levels in monocyte cultures and synovial fluids. Journal of Immunological Methods, 170, 125-135.
35. Dossus, L., Becker, S., Achaintre, D., Kaaks, R, & Rinaldi, S. (2009). Validity of multiplex-based assays for cytokine measurements in serum and plasma from "non-diseased" subjects: comparison with ELISA. Journal of Immunological Methods, 350, 125-132.
36. Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C, Leslie, K., Madhoo, S., et al. (2009). In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. The Journal of Experimental Medicine, 206, 1029-1036.
37. Granowitz, E. V., Santos, A., Poutsiaka, D. D., Cannon, J. G, Wilmore, D. A., Wolff, S. M., et al. (1991). Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet, 338, 1423-1424.
38. Fischer, E., van Zee, K. J., Marano, M. A., Rock, C. S., Kenney, J. S., Poutsiaka, D. D., et al. (1992). Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood, 79, 2196-2200.
39. Kopp, W. C, Urba, W. J., Rager, H. C, Alvord, W. G, Oppenheim, J. J., Smith, J. W., 2nd, et al. (1996). Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clinical Cancer Research, 2, 501-506.
40. Atkins, M. B., Vachino, G, Tilg, H. J., Karp, D. D., Robert, N. J., Kappler, K., et al. (1992). Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. Journal of Clinical Oncology, 10, 1802-1809.
41. Gabay, C, Smith, M. F., Eidlen, D., & Arend, W. P. (1997). Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. Journal of Clinical Investigation, 99, 2930-2940.
42. Lamacchia, C, Palmer, G, Eemayer, C. A., Alabot-Ayer, D., & Gabay, C. (2010). Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cellspecific interleukin-1 receptor antagonist. Arthritis and Rheumatism, 62, 452-462.
43. Fuksiewicz, M., Kaminska, J., Kotowicz, B., Kowalska, M., Rubach, M., & Pienkowski, T. (2006). Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients. Clinical Chemistry and Laboratory Medicine, 44, 1092-1097.
44. *2) is associated with a decreased risk of primary lung cancer. Cancer Letters, 236, 269-275.
45. Rafiq, S., Stevens, K., Hurst, A. J., Murray, A., Henley, W., Weedon, M. N., et al. (2007). Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes and Immunity, 8, 344-351.
46. Graziano, F., Ruzzo, A., Canestrari, E., Loupakis, F., Santini, D., Rulli, E., et al. (2009). Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. The Pharmacogenomics Journal, 9, 78-84.
47. Rambaldi, A., Torcia, M., Bettoni, S., Barbui, T., Vannier, E., Dinarello, C. A., et al. (1991). Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood, 78, 3248-3253.
48. Estrov, Z., Kurzrock, R., Estey, E., Wetzler, M., Kantarjian, H., Blake, M., et al. (1992). Inhibition of acute myelogenous leukemia proliferation by IL-1 receptor antagonist and soluble IL-1 receptors. Blood, 79, 1938-1945.
49. Kurzrock, R. (2001). Cytokine deregulation in cancer. Biomedicine & Pharmacotherapy, 55, 543-547.
50. Ferretti, M., Casini-Raggi, V., Pizarro, T. T., Eisenberg, S. P., Nast, C. C., & Cominelli, F. (1994). Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. Journal of Clinical Investigation, 94, 449-453.
51. Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., et al. (2000). Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. The Journal of Experimental Medicine, 191, 313-320.
52. Nicklin, M. J., Hughes, D. E., Barton, J. L., Ure, J. M., & Duff, G. W. (2000). Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. The Journal of Experimental Medicine, 191, 303-312.
53. Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009). Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care, 32, 1663-1668.
54. Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., et al. (2009). An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. The New England Journal of Medicine, 360, 2426-2437.
55. Reddy, S., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., et al. (2009). An autoinflammatory disease due to homozygous deletion of the IL1RN locus. The New England Journal of Medicine, 360, 2438-2444.
56. Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005). Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. The Journal of Experimental Medicine, 201, 1479-1486.
57. Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., et al. (2006). Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. The New England Journal of Medicine, 355, 581-592.
58. Gattorno, M., Tassi, S., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., et al. (2007). Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis and Rheumatism, 56, 3138-3148.
59. Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., et al. (2007). Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England Journal of Medicine, 356, 2582-2590.
60. Torcia, M., Lucibello, M., Vannier, E., Fabiani, S., Miliani, A., Guidi, G., et al. (1996). Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Experimental Hematology, 24, 868-874.
61. Lust, J. A., & Donovan, K. A. (1999). The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematology/Oncology Clinics of North America, 13, 1117-1125.
62. Bar, D., Apte, R. N., Voronov, E., Dinarello, C. A., & Cohen, S. (2004). A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. The FASEB Journal, 18, 161-163.
63. Olson, J. L., Courtney, R. J., Rouhani, B., Mandava, N., & Dinarello, C. A. (2009). Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model. Ocular Immunology and Inflammation, 17, 195-200.
64. Apte, R. N., Dotan, S., Elkabets, M., White, M. R., Reich, E., Carmi, Y., et al. (2006). The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer and Metastasis Reviews, 25, 387-408.
65. Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., et al. (2005). CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting Cells. Journal of Immunology, 175, 8200-8208.
66. Zoller, M., Douvdevani, A., Segal, S., & Apte, R. N. (1992). Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response. International Journal of Cancer, 50, 450-457.
67. Colombo, M. P., & Mantovani, A. (2005). Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Research, 65, 9113-9116.
68. Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M. R., et al. (2010). Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proceedings of the National Academy of Sciences of the United States of America, 107, 2574-2579.
69. Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., et al. (2007). Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The New England Journal of Medicine, 356, 1517-1526.
70. Donath, M. Y., Weder, C., Brunner, A., Keller, C., Whitemore, J., Der, K., et al. (2009). XOMA 052, a potential disease modifying anti-1L-1beta antibody, shows sustained HbA1c reductions 3 Months after a single injection with no increases in safety parameters in subjects with Type 2 diabetes. Diabetes, 58, A30.
71. Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., et al. (2009). Use of canakinumab in the cryopyrin-associated periodic syndrome. New England Journal of Medicine, 360, 2416-2425.
72. Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., et al. (2008). Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis and Rheumatism, 58, 2443-2452.
73. Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice. Oncology, 3, 24-40.
74. Wu, H.-C., Huang, C.-T., & Chang, D.-K. (2008). Anti-angiogenic therapeutic drugs fro treatment of human cancer. J Cancer Molecules, 4, 37-45.
75. Mokart, D., Capo, C., Blache, J. L., Delpero, J. R., Houvenaeghel, G., Martin, C., et al. (2002). Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. The British Journal of Surgery, 89, 1450-1456.
76. Bower, J. E., Ganz, P. A., Aziz, N., & Fahey, J. L. (2002). Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosomatic Medicine, 64, 604-611.
77. Rutkowski, P., Kaminska, J., Kowalska, M., Ruka, W., & Steffen, J. (2003). Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. Journal of Surgical Oncology, 84, 151-159.
78. Fujiwaki, R., Iida, K., Nakayama, K., Kanasaki, H., Hata, K., Katabuchi, H., et al. (2003). Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecologic Oncology, 89, 77-83.
79. Schmid, I., Schmitt, M., Streiter, M., Meilbeck, R., Haas, R. J., & Stachel, D. K. (2005). Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia. European Journal of Medical Research, 10, 457-461.
80. Laurencet, F. M., Chapuis, B., Roux-Lombard, P., Dayer, J. M., & Beris, P. (1994). Malignant histiocytosis in the leukaemic stage: a new entity (M5c-AML) in the FAB classification? Leukemia, 8, 502-506.
81. Barak, V., Nisman, B., Polliack, A., Vannier, E., & Dinarello, C. A. (1998). Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. European Cytokine Network, 9, 33-39.
82. Ito, H., & Miki, C. (1999). Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients. Scandinavian Journal of Gastroenterology, 34, 1139-1143.
83. Tao, M., Li, B., Nayini, J., Andrews, C. B., Huang, R. W., Devemy, E., et al. (2000). SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine, 12, 699-707.
84. Kaminska, J., Kowalska, M. M., Nowacki, M. P., Chwalinski, M. G., Rysinska, A., & Fuksiewicz, M. (2000). CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathology Oncology Research, 6, 38-41.
85. Orre, I. J., Murison, R., Dahl, A. A., Ueland, T., Aukrust, P., & Fossa, S. D. (2009). Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain, Behavior, and Immunity, 23, 868-874.
86. Niedzwiecki, S., Stepien, T., Kuzdak, K., Stepien, H., Krupinski, R., Seehofer, D., et al. (2008). Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbeck's Archives of Surgery, 393, 275-280.
87. Poch, B., Lotspeich, E., Ramadani, M., Gansauge, S., Beger, H. G., & Gansauge, F. (2007). Systemic immune dysfunction in pancreatic cancer patients. Langenbeck's Archives of Surgery, 392, 353-358.
88. Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L., & Kurzrock, R. (2004). Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer, 101, 2727-2736.
89. Graziano, F., Ruzzo, A., Santini, D., Humar, B., Tonini, G., Catalano, V., et al. (2005). Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. Journal of Clinical Oncology, 23, 2339-2345.
90. Mustea, A., Pirvulescu, C., Konsgen, D., Braicu, E. I., Yuan, S., Sun, P., et al. (2008). Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine, 42, 77-84.
91. Bruserud, O., Aasen, I., Akselsen, P. E., Bergheim, J., Rasmus-sen, G., & Nesthus, I. (1996). Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia. European Journal of Haematology, 57, 87-95.
92. Gherardi, R. K., Belec, L., Soubrier, M., Malapert, D., Zuber, M., Viard, J. P., et al. (1996). Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood, 87, 1458-1465. (Pubitemid 26056910)
93. Iwagaki, H., Hizuta, A., & Tanaka, N. (1997). Interleukin-1 receptor antagonists and other markers in colorectal cancer patients. Scandinavian Journal of Gastroenterology, 32, 577-581.
94. Parekh, D. J., Ankerst, D. P., Baillargeon, J., Higgins, B., Platz, E. A., Troyer, D., et al. (2007). Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiology, Biomarkers & Prevention, 16, 1966-1972.
95. *). Annual Review of Immunology, 27, 621-668.
96. Mitroulis, I., Papadopoulos, V. P., Konstantinidis, T., & Ritis, K. (2008). Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. The Netherlands Journal of Medicine, 66, 489-491.
97. Calligaris, L., Marchetti, F., Tommasini, A., & Ventura, A. (2008). The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. European Journal of Pediatrics, 167, 695-696.
98. Bodar, E. J., Simon, A., de Visser, M., & van der Meer, J. W. (2009). Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). The Netherlands Journal of Medicine, 67, 302-305.
99. Bodar, E. J., van der Hilst, J. C., Drenth, J. P., van der Meer, J. W., & Simon, A. (2005). Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. The Netherlands Journal of Medicine, 63, 260-264.
100. Rigante, D., Ansuini, V., Bertoni, B., Pugliese, A. L., Avallone, L., Federico, G., et al. (2006). Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatology International, 27, 97-100.
101. Cailliez, M., Garaix, F., Rousset-Rouviere, C., Bruno, D., Kone-Paut, I., Sarles, J., et al. (2006). Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. Journal of Inherited Metabolic Disease, 29, 763.
102. Fitzgerald, A. A., Leclercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A. (2005). Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis and Rheumatism, 52, 1794-1803.
103. Lequerre, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. (2008). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Annals of the Rheumatic Diseases, 67, 302-308.
104. Ohlsson, V., Baildam, E., Foster, H., Jandial, S., Pain, C., Strike, H., et al. (2008). Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford), 47, 555-556.
105. Mirkinson, L. J., Nagle, D., Kadom, N., & Jones, O. Y. (2006). Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis. Journal of Clinical Rheumatology, 12, 83-86.
106. Botsios, C., Sfriso, P., Furlan, A., Punzi, L., & Dinarello, C. A. (2008). Resistant Behçet disease responsive to anakinra. Annals of Internal Medicine, 149, 284-286.
107. De Koning HD, Bodar EJ, Simon A, Van der Hilst JCH, Netea MG, Van der Meer JW (2005) Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis, J. C. H
108. Eiling, E., Moller, M., Kreiselmaier, I., Brasch, J., & Schwarz, T. (2007). Schnitzler syndrome: treatment failure to rituximab but response to anakinra. Journal of the American Academy of Dermatology, 57, 361-364.
109. Adam, Z., Krejci, M., Pour, L., Neubauer, J., Prasek, J., & Hajek, R. (2008). Schnitzler syndrome-report on a fourteen-year course of the disease and an overview of information on the disease. Vnitrní Lé karství, 54, 1140-1153.
110. Simon, A., Bodar, E. J., van der Hilst, J. C. H., Van der Meer, J. W., Fiselier, T. J. W., Cuppen, M. P. J. M., et al. (2004). Beneficial response to interleukin-1 receptor antagonist in TRAPS. The American Journal of Medicine, 117, 208-210. (Pubitemid 39055877)
111. Sacre, K., Brihaye, B., Lidove, O., Papo, T., Pocidalo, M. A., Cuisset, L., et al. (2008). Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. The Journal of Rheumatology, 35, 357-358.
112. Gattorno, M., Pelagatti, M. A., Meini, A., Obici, L., Barcellona, R., Federici, S., et al. (2008). Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis and Rheumatism, 58, 1516-1520.
113. Brenner, M., Ruzicka, T., Plewig, G., Thomas, P., & Herzer, P. (2009). Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. The British Journal of Dermatology, 161, 1199-1201.
114. Kelly, A., & Ramanan, A. V. (2008). A case of macrophage activation syndrome successfully treated with anakinra. Nature Clinical Practice. Rheumatology, 4, 615-620.
115. Chou, R. C., Dinarello, C. A., Ferry, J. A., & Dal Cin, P. (2010). A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia. Arthritis Care and Research, 62, 137-140.
116. Botsios, C., Sfriso, P., Punzi, L., & Todesco, S. (2007). Noncomplementaemic urticarial vasculitis: Successful treatment with the IL-1 receptor antagonist, anakinra. Scandinavian Journal of Rheumatology, 36, 236-237.
117. Furlan, A., Botsios, C., Ruffatti, A., Todesco, S., & Punzi, L. (2008). Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint, Bone, Spine, 75, 366-367.
118. Chauffier, K., London, J., Beaudouin, C., & Fautrel, B. (2009). Indications of anakinra. La Presse Médicale, 38, 799-807.
119. So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007). A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Research & Therapy, 9, R28.
120. Terkeltaub, R., Sundy, J. S., Schumacher, H. R., Murphy, F., Bookbinder, S., Biedermann, S., et al. (2009). The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomised, single-blind pilot study. Annals of the Rheumatic Diseases, 68, 1613-1617.
121. Singh, D., & Huston, K. K. (2009). IL-1 inhibition with anakinra in a patient with refractory gout. Journal of Clinical Rheumatology, 15, 366.
122. Gratton, S. B., Scalapino, K. J., & Fye, K. H. (2009). Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis and Rheumatism, 61, 1268-1270.
123. McGonagle, D., Tan, A. L., Shankaranarayana, S., Madden, J., Emery, P., & McDermott, M. F. (2007). Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Annals of the Rheumatic Diseases, 66, 1683-1684.
124. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GL, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CF, Varma A, Gelwix C, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW (2010) Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling following acute myocardial infarction. Am J Cardiology in press
125. Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., et al. (2009). Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis and Rheumatism, 61, 344-352.